Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through extensive database of analyst ratings, including by analyst accuracy. Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. CVS Health Corp (NYSE: CVS ) Dividend Yield: 3.02% UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $126 to $118 on Sept. 3, 2026. This analyst has an accuracy rate of 70%. Argus Research analyst Steve Silver maintained a Buy rating and boosted the price target from $104 to $114 on Aug. 19, 2026. This analyst has an accuracy rate of 59%. Recent News: CVS Health said it will hold a conference call on Wednesday, Nov. 4, to discuss third quarter financial results. Pro’s real-time newsfeed alerted to latest CVS news. Medtronic PLC (NYSE: MDT ) Dividend Yield: 3.37% Barclays analyst Christopher Pasquale initiated coverage on the stoc
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. 02% UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $126 to $118 on Sept. 3, 2026. This analyst has an accuracy rate of 70%.
Argus Research analyst Steve Silver maintained a Buy rating and boosted the price target from $104 to $114 on Aug. 19, 2026. This analyst has an accuracy rate of 59%. Recent News: CVS Health said it will hold a conference call on Wednesday, Nov.
4, to discuss third quarter financial results. Pro’s real-time newsfeed alerted to latest CVS news. 37% Barclays analyst Christopher Pasquale initiated coverage on the stock with an Overweight rating and a price target of $95 on Oct. 7, 2026.
This analyst has an accuracy rate of 69%. TD Cowen analyst Joshua Jennings maintained a Buy rating and increased the price target from $100 to $110 on Sept. 30, 2026. This analyst has an accuracy rate of 56%.
Recent News: On Oct. 1, Medtronic disclosed that the American Medical Association approved new Category I Current Procedural Terminology codes for two of its technologies. 87% Barclays analyst James Gordon downgraded the stock from Equal-Weight to Underweight on Jan. 6, 2026.
This analyst has an accuracy rate of 76%. Jefferies analyst Michael Leuchten upgraded the stock from Hold to Buy on Oct. 27, 2025. This analyst has an accuracy rate of 60%.
Recent News: On Sept. 14, GSK announced positive clinical data from two separate lung cancer trials, demonstrating significant efficacy and survival benefits across different patient populations. Pro’s real-time newsfeed alerted to latest GSK news Photo via Shutterstock